Abstract:BackgroundGene expression profiling has been used to define molecular phenotypes of complex diseases such as breast cancer. The luminal A and basal-like subtypes have been repeatedly identified and validated as the two main subtypes out of a total of five molecular subtypes of breast cancer. These two are associated with distinctly different gene expression patterns and more importantly, a significant difference in clinical outcome. To further validate and more thoroughly characterize these two subtypes at the molecular level in tumors at an early stage, we report a gene expression profiling study using three different DNA microarray platforms.ResultsExpression data from 20 tumor biopsies of early stage breast carcinomas were generated on three different DNA microarray platforms; Applied Biosystems Human Genome Survey Microarrays, Stanford cDNA Microarrays and Agilent's Whole Human Genome Oligo Microarrays, and the resulting gene expression patterns were analyzed. Both unsupervised and supervised analyses identified the different clinically relevant subtypes of breast tumours, and the results were consistent across all three platforms. Gene classification and biological pathway analyses of the genes differentially expressed between the two main subtypes revealed different molecular mechanisms descriptive of the two expression-based subtypes: Signature genes of the luminal A subtype were over-represented by genes involved in fatty acid metabolism and steroid hormone-mediated signaling pathways, in particular estrogen receptor signaling, while signature genes of the basal-like subtype were over-represented by genes involved in cell proliferation and differentiation, p21-mediated pathway, and G1-S checkpoint of cell cycle-signaling pathways. A minimal set of 54 genes that best discriminated the two subtypes was identified using the combined data sets generated from the three different array platforms. These predictor genes were further verified by TaqMan® Gene Expression assays.ConclusionWe have identified and validated the two main previously defined clinically relevant subtypes, luminal A and basal-like, in a small set of early stage breast carcinomas. Signature genes characterizing these two subtypes revealed that distinct molecular mechanisms might have been pre-programmed at an early stage in different subtypes of the disease. Our results provide further evidence that these breast tumor subtypes represent biologically distinct disease entities and may require different therapeutic strategies. Finally, validated by multiple gene expression platforms, including quantitative PCR, the set of 54 predictor genes identified in this study may define potential prognostic molecular markers for breast cancer.

Biological characterization of the basal-like subtype of invasive breast carcinoma

Abstract P5-04-03: Epithelial-mesenchymal Transition is Associated with in Situ to Invasive Transition of Basal-Like Breast Cancer

A Clinicopathological Study of Basal-Like Breast Carcinoma

[Relationship Between Breast Cancer Molecular Subtypes with Clinicopathological Characteristics and Prognosis].

MRI and Pathological Features of Different Molecular Subtypes of Breast Cancers

A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard

Study on Clinicopathological Classification and Clinical and Pathological Characteristics in Breast Cancer

Characteristics and prognosis for molecular breast cancer subtypes in Chinese women

Integrative Analysis Identifies Two Molecular and Clinical Subsets in Luminal B Breast Cancer

WNT5B governs the phenotype of basal-like breast cancer by activating WNT signaling

Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Clinical significance of four subtypes of breast cancer

Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer

Pathological features and prognosis of different molecular subtypes of breast cancer

Network Analysis Identifies Regulators of Basal-Like Breast Cancer Reprogramming and Endocrine Therapy Vulnerability

Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas

Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies

Clinical Characteristics and Prognosis of Different Subtypes of Breast Cancer

Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature

Clinicopathological features of Luminal B-like breast cancer